| 0.4299 -0.019 (-4.28%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.56 | 1-year : | 0.65 |
| Resists | First : | 0.47 | Second : | 0.56 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.39 | Second : | 0.34 |
| MAs | MA(5) : | 0.42 |
MA(20) : | 0.4 |
| MA(100) : | 0.53  |
MA(250) : | 0.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 72.3 |
D(3) : | 63.6 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 1.12 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FEMY ] has closed below upper band by 25.0%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.46 - 0.46 | 0.46 - 0.47 |
| Low: | 0.4 - 0.41 | 0.41 - 0.41 |
| Close: | 0.43 - 0.43 | 0.43 - 0.43 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Fri, 08 May 2026
[10-Q] FEMASYS INC Quarterly Earnings Report - Stock Titan
Fri, 08 May 2026
Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filed - Stock Titan
Fri, 08 May 2026
Femasys starts birth-control trial as it expands fertility care - Stock Titan
Tue, 05 May 2026
Femasys pushes fertility treatment into OB/GYN offices with first paid use - Stock Titan
Tue, 05 May 2026
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete - Sahm
Mon, 04 May 2026
MSN Money - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 60 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 1,930 (K) |
| Shares Short P.Month | 1,990 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -568.4 % |
| Return on Assets (ttm) | -66.3 % |
| Return on Equity (ttm) | -455.8 % |
| Qtrly Rev. Growth | 39.9 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.92 |
| PEG Ratio | 0 |
| Price to Book value | 4.29 |
| Price to Sales | 11.33 |
| Price to Cash Flow | -1.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|